Furthermore, the results in the subcutaneous tumor model showed that tumor growth was inhibited more significantly in the Hepa1‐6 shDtx2 group than in the Hepa1‐6 wild‐type group following treatment with the PD‐1 antibody, and this effect was accompanied by a lower tumor burden and longer overall survival time (Figure S13A–D, Supporting Information). Here, PDCD1 is linked to neoplasm.